Invest now
Natco Pharma Balance Sheet Annual
BSE: 524816 | NSE: NATCOPHARM | ISIN: INE987B01026 | Sector: Biotechnology & Drugs819.00 0.00 (0.00%)Updated : 11 Sep 2026
Research on
| Fiscal Period | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Period End Date | Mar 26 | Mar 25 | Mar 24 | Mar 23 |
| Total Liabilities Shareholders' Equity | 11,073.70 | 8,630.80 | 6,906.30 | 5,657.40 |
| Accumulated Depreciation Total | -1,354.90 | -1,249.50 | -1,063.80 | -912.30 |
| Cash Equivalents | 57.80 | 53.90 | 6.30 | - |
| Other Liabilities Total | 67.30 | 70.20 | 74.90 | 87.00 |
| Accrued Expenses | 71.00 | 65.00 | 57.50 | 44.60 |
| Long Term Debt | 100.00 | - | - | - |
| Common Stock Total | 35.80 | 35.80 | 35.80 | 36.50 |
| Other Current Assets Total | 668.30 | 324.70 | 390.00 | 336.40 |
| Prepaid Expenses | 22.10 | 30.50 | 28.90 | 28.30 |
| Total Assets | 11,073.70 | 8,630.80 | 6,906.30 | 5,657.40 |
| Current Portof LT Debt/ Capital Leases | 303.30 | 1.70 | 2.70 | 0.60 |
| Additional Paid- In Capital | 1,201.90 | 1,201.90 | 1,201.90 | 1,406.50 |
| Cash | 141.10 | 66.10 | 64.10 | 131.90 |
| Total Equity | 9,221.10 | 7,607.00 | 5,853.10 | 4,873.80 |
| Long Term Investments | 2,588.90 | 309.40 | 120.90 | 87.40 |
| Retained Earnings( Accumulated Deficit) | 7,701.50 | 6,359.50 | 4,578.60 | 3,404.50 |
| Total Common Shares Outstanding | 17.91 | 17.91 | 17.91 | 18.25 |
| Property/ Plant/ Equipment Total- Gross | 4,194.00 | 3,906.80 | 3,498.80 | 3,215.70 |
| Tangible Book Valueper Share Common Eq | 500.46 | 409.85 | 316.01 | 256.81 |
| Goodwill Net | 63.00 | 57.40 | 56.00 | 55.20 |
| Total Liabilities | 1,852.60 | 1,023.80 | 1,053.20 | 783.60 |
| Total Debt | 713.90 | 279.40 | 371.20 | 166.70 |
| Short Term Investments | 1,925.60 | 2,369.90 | 1,320.80 | 661.20 |
| Cashand Short Term Investments | 2,124.50 | 2,489.90 | 1,391.20 | 793.10 |
| Total Receivables Net | 1,247.60 | 1,575.50 | 1,421.70 | 1,033.60 |
| Notes Payable/ Short Term Debt | 306.40 | 273.10 | 363.20 | 165.00 |
| Deferred Income Tax | 0.20 | 0.20 | 0.20 | 12.40 |
| Accounts Receivable- Trade Net | 954.00 | 1,347.00 | 1,255.30 | 884.60 |
| Property/ Plant/ Equipment Total- Net | 2,839.10 | 2,657.30 | 2,435.00 | 2,303.40 |
| Minority Interest | 0.00 | 5.30 | - | 0.00 |
| Total Current Liabilities | 1,680.90 | 943.50 | 972.80 | 683.10 |
| Total Inventory | 989.80 | 849.40 | 791.70 | 808.90 |
| Accounts Payable | 409.30 | 274.90 | 235.50 | 263.80 |
| Other Currentliabilities Total | 590.90 | 328.80 | 313.90 | 209.10 |
| Total Long Term Debt | 104.20 | 4.60 | 5.30 | 1.10 |
| Intangibles Net | 194.30 | 208.70 | 137.10 | 132.60 |
| Other Long Term Assets Total | 252.10 | 68.90 | 37.20 | 16.90 |
| Note Receivable- Long Term | 84.00 | 59.10 | 96.60 | 61.60 |
| Unrealized Gain( Loss) | 281.90 | - | - | - |
| period Length | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 5,052.30 | 5,270.00 | 4,023.50 | 3,000.30 |
| Capital Lease Obligations | 4.20 | 4.60 | 5.30 | 1.10 |
| Other Equity Total | - | 9.80 | 36.80 | 26.30 |
*All figures in crores except per share values
Natco Pharma Quick Links
Natco Pharma Dividend Natco Pharma Bonus Natco Pharma News Natco Pharma AGM Natco Pharma Rights Natco Pharma Splits Natco Pharma Board Meetings Natco Pharma Key Metrics Natco Pharma Shareholdings Natco Pharma Profit Loss Natco Pharma Cashflow Natco Pharma Q1 Results Natco Pharma Q2 Results Natco Pharma Q3 Results Natco Pharma Q4 Results
Equity Quick Links
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks
272.00+6.05(2.27%)
1,260.00+20.50(1.65%)
11,053.00+157.00(1.44%)
1,196.80-29.75 (-2.43%)
185.95-2.60 (-1.38%)
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.